title: Five years later: re-examining the financial burden of boosting with Norvir.
authors.forename: Carina
authors.initials: C
authors.lastname: Marquez
authors.forename: B Joseph
authors.initials: BJ
authors.lastname: Guglielmo
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Klausner
mesh_terms: D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000331:legislation & jurisprudence; D017320:HIV Protease Inhibitors / Q000191:economics*; D006801:Humans; D019438:Ritonavir / Q000191:economics*; D014481:United States
chemical_list: D017320:HIV Protease Inhibitors; D019438:Ritonavir